Active TB screening may be cost saving in high-incidence Inuit communities in Canada Clinical study 13 November 2021 Pages: 1 - 1
Acute care costs of neonatal sepsis and meningitis in Africa Clinical study 13 November 2021 Pages: 2 - 2
Baricitinib + SOC cost effective vs SOC for patients hospitalised with COVID-19 in the USA Clinical study 13 November 2021 Pages: 3 - 3
Cancer care in the USA presents substantial economic burden for patients Clinical study 13 November 2021 Pages: 4 - 4
Continuous monitoring technology improves outcomes and reduce costs in acute-care setting Clinical study 13 November 2021 Pages: 5 - 5
Costs high after triple drug class therapy for multiple melanoma Clinical study 13 November 2021 Pages: 6 - 6
Counting the cost of COVID-19 at the peak of the pandemic in Spain Clinical study 13 November 2021 Pages: 7 - 7
Dapagliflozin cost effective vs sulfonylureas as second-line therapy for T2DM in India Clinical study 13 November 2021 Pages: 8 - 8
Dapagliflozin good value for money for diabetic patients with reduced LVEF in the USA Clinical study 13 November 2021 Pages: 9 - 9
Decision-support tool for ICU discharge improves outcomes at acceptable cost Non-clinical study 13 November 2021 Pages: 10 - 10
Empagliflozin less costly than other branded AHAs for T2DM patients with CVD in the USA Clinical study 13 November 2021 Pages: 11 - 11
FreeStyle Libre Flash cost effective for glucose monitoring Clinical study 13 November 2021 Pages: 12 - 12
Government spending on childhood immunisation increases Clinical study 13 November 2021 Pages: 13 - 13
High-flow nasal cannula use cost effective in infants hospitalised with bronchiolitis in Colombia Unknown 13 November 2021 Pages: 14 - 14
Insulin glargine/lixisenatide good value in type 2 diabetes Clinical study 13 November 2021 Pages: 15 - 15
Lower back pain a substantial economic burden in Switzerland Clinical study 13 November 2021 Pages: 16 - 16
MRI-guided IV alteplase therapy worth it for stroke with unknown time of onset in Germany Clinical study 13 November 2021 Pages: 18 - 18
No benefit of peritoneal dialysis over haemodialysis for uninsured ESKD patients in the USA Clinical study 13 November 2021 Pages: 19 - 19
Oral semaglutide a cost-effective option for patients with uncontrolled T2DM Clinical study 13 November 2021 Pages: 20 - 20
PCSK9 inhibitors not cost effective versus other antihyperlipidaemics Clinical study 13 November 2021 Pages: 21 - 21
Prescription digital therapeutic, reSET-O, saves costs in US patients with opioid use disorder Clinical study 13 November 2021 Pages: 22 - 22
Remote pulse-ox monitoring for COVID-19 patients saves costs, improves outcomes in the USA Clinical study 13 November 2021 Pages: 23 - 23
Rivaroxaban reduces HRU, costs vs warfarin for AF in US patients with obesity and diabetes Clinical study 13 November 2021 Pages: 24 - 24
STEP-KOA knee osteoarthritis programme is cost effective in VA population in the USA Clinical study 13 November 2021 Pages: 25 - 25
Suboptimal lipid-lowering therapy in secondary prevention of atherosclerotic CVD incurs high cost in Italy Clinical study 13 November 2021 Pages: 26 - 26
Tumour molecular classification-guided treatment cost effective for stage I or II high-risk EC Clinical study 13 November 2021 Pages: 27 - 27
Unilateral cochlear implants cost effective in adults in UK Clinical study 13 November 2021 Pages: 28 - 28
Universal HCV testing of pregnant women would be cost effective in Ireland Clinical study 13 November 2021 Pages: 29 - 29
Vedolizumab cost effective versus adalimumab for ulcerative colitis Clinical study 13 November 2021 Pages: 30 - 30
ICER revised report: tezepelumab reduces asthma exacerbations but questions remain News item 13 November 2021 Pages: 31 - 31
New NICE guideline for diagnosis and management of myalgic encephalopathy/chronic fatigue syndrome Media release 13 November 2021 Pages: 32 - 32
NICE draft guidance recommends dapagliflozin for some patients with chronic kidney disease Unknown 13 November 2021 Pages: 33 - 33
NZ's Pharmac negotiates deal for Roche's monoclonal antibodies for COVID-19 News item 13 November 2021 Pages: 34 - 34
NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19 News item 13 November 2021 Pages: 35 - 35
Scottish Medicines Consortium accepts three new medicines and rejects one News item 13 November 2021 Pages: 36 - 36
UK's NICE does not recommend tucatinib for HER2-positive metastatic breast cancer News item 13 November 2021 Pages: 37 - 37